Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 1 Interventional

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

NCT00464321
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
GC1008
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 21, 2026, 1:36 AM EDT
Recruiting No phase listed Observational

Precision Medicine Approaches to Renal Osteodystrophy

NCT05880914
View directory record Official record
Conditions
Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions
miRNAseq analysis, Standard treatment for bone disorder
Procedure · Drug
Lead sponsor
Thomas Nickolas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

NCT03873402
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Ipilimumab placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Athens, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 21, 2026, 1:36 AM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vasopressin and the Social Brain

NCT02394054
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal vasopressin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Not applicable Interventional Results available

Optimizing Electronic Alerts for Acute Kidney Injury

NCT02753751
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AKI Alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 21, 2026, 1:36 AM EDT
Not yet recruiting No phase listed Observational

Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring

NCT07880795
View directory record Official record
Conditions
End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 1 Interventional

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

NCT02897375
View directory record Official record
Conditions
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions
Carboplatin, Cisplatin, Palbociclib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

NCT00888290
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Placebos
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

NCT01175382
View directory record Official record
Conditions
Overactive Bladder, Lower Urinary Tract Symptoms
Interventions
Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
Behavioral · Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 21, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

NCT03552380
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Entinostat, Nivolumab, Ipilimumab
Drug
Lead sponsor
Roberto Pili
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 21, 2026, 1:36 AM EDT
Terminated Not applicable Interventional Results available

Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT02517996
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 21, 2026, 1:36 AM EDT
Not listed No phase listed Observational

MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery

NCT01918046
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Not applicable Interventional Results available

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

NCT01350388
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 21, 2026, 1:36 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Not applicable Interventional Results available

eCoin for OAB Feasibility Follow-on Study

NCT03655054
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

NCT00405327
View directory record Official record
Conditions
Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions
Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
Biological · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 1:36 AM EDT
Suspended Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727
View directory record Official record
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder

NCT02922842
View directory record Official record
Conditions
Urge Incontinence, Overactive Bladder
Interventions
Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Not applicable Interventional

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

NCT01505569
View directory record Official record
Conditions
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions
Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Drug · Biological · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 1:36 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

NCT02537431
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 21, 2026, 1:36 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor

NCT00187031
View directory record Official record
Conditions
Wilms Tumor
Interventions
Topotecan, Filgrastim (G-CSF), Pegfilgrastim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 21, 2026, 1:36 AM EDT